Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
08.01.2024 - - Approximately $19 million and $28 million of net revenue from sales of LUMRYZ estimated for the fourth quarter and full year 2023, respectively - - Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in ... Seite 1
Greg Divis Emisar Optum Avadel Pharmaceuticals Supplemental New Drug Application Orphan Drug Chief Executive Officer
Source: wallstreet-online.de